Director, HEOR

Kura Oncology, Inc. · San Diego, CA

Company

Kura Oncology, Inc.

Location

San Diego, CA

Type

Full Time

Job Description

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

The Director, HEOR is responsible for developing and performing the value evidence generation and dissemination strategy for health economic and outcomes research (HEOR) including real-world evidence (RWE) and clinical outcomes assessments (COAs). This individual will oversee planning and execution for all activities involved in developing HEOR strategies and tactics to gain and maintain market access and reimbursement for Kura’s lead pipeline product.

ESSENTIAL JOB FUNCTIONS:

  • Shape HEOR strategies to generate evidence of the value of Kura’s lead asset, in alignment with the brand strategic plan, and integrate within core medical plans, value & access plans, evidence generation plans, and launch excellence plans
  • Establish an integrated HEOR plan aligned with Commercial, Medical, Market Access, and Scientific objectives
  • Ensure HEOR strategies, plans and tactical executions are evidence based, scientifically and technically valid, and medically relevant; of clinical, humanistic, and economical importance; patient focused; address the needs of regional regulators, HTA, patients, health care providers, and policy makers and regulators
  • Oversee and guide development and implementation of patient reported outcomes (PRO) and COA end points strategy
  • Lead the development of value story, value dossiers, economic models, and planning for health technology assessments (HTAs) to demonstrate the value of Kura’s therapies
  • Actively monitor the changing healthcare landscape to identify and integrate emerging HEOR trends
  • Support preparation and coordination for HTA/payer advice, mock preparations, submissions, face to face meetings and objection handling
  • Represent Kura on HEOR issues at key forums, conferences and professional associations and trade associations, including monitoring ad communicating activities by such forums to executive leadership
  • Deliver distinctive ways to disseminate evidence appropriately to demonstrate compelling value propositions for population health decision-makers/payers
  • Use distinctive approaches for proactive evidence dissemination in a compliant manner
  • Direct and implement relevant HEOR initiatives with external entities
  • Contribute to development and execution of overall and HEOR-specific publication plans
  • Other duties as assigned

JOB SPECIFICATIONS:

  • Master's or Doctorate degree in public health, medicine, pharmacy, economics, epidemiology, health services research or HEOR-related field
  • 8+ years experience in pharmaceutical industry, with 5+ years of direct experience in HEOR (Real World Evidence, Patient Reported Outcomes, Clinical Outcomes Assessment, Health Policy, Population Health, etc.)
  • Experience in outcomes research methodologies (retrospective observational cohort, cross-sectional studies, registries, etc.) to support product development and reimbursement efforts is required
  • Experience with execution of scientifically robust qualitative and quantitative studies, development and validation of COA measures including assisting clinical development teams in implementing COAs in clinical trials to measure patient relevant endpoints
  • Hematology/oncology experience with interactions with US and ex-US reimbursement agencies is preferred
  • Understanding of the global healthcare environment, clinical research processes, global regulations, and ethical guidelines
  • Highly-developed communications skills (written/verbal) and interpersonal savvy
  • Ability to create, track and plan timelines and budgets
  • Excellent organization and multi-tasking skills
  • Ability to accommodate shifting priorities, demands and timelines
  • Knowledge of regulatory guidance documents and scientific guidelines (FDA guidance; FDA qualification documentation; dossier outline; EMA guidance resources; ISPOR Task Force Documents, etc.) • Understanding of instrument development and validation process
  • Strong computer skills (Microsoft Office, etc.) and knowledge of database management (Veeva Vault, etc.)
  • Travel (up to 40%) for conferences, meetings, and HEOR project or team-management related business

The base range for a Director is $218,236 - $246,845 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura’s Values that are used for candidate selection and performance assessments:

  • We work as one for patients
  • We are goal-focused and deliver with excellence
  • We are science-driven courageous innovators
  • We strive to bring out the best in each other and ourselves

The Kura Package

  • Career advancement/ development opportunities
  • Competitive comp package
  • Bonus
  • 401K + Employer contributions
  • Generous stock options
  • ESPP Plan
  • 20 days of PTO to start
  • 18 Holidays  (Including Summer & Winter Break)
  • Generous Benefits Package with a variety of plans available with a substantial employer match
  • Paid Paternity/Maternity Leave
  • In-Office Catered lunches
  • Home Office Setup
  • Lifestyle Spending Stipend
  • Commuter Stipend (Boston Office)
  • Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com. 

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. 

Apply Now

Date Posted

10/25/2023

Views

12

Back to Job Listings Add To Job List Company Profile View Company Reviews
Neutral
Subjectivity Score: 0.5